Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 4/20 | 0.50 |
| ▸ | XDH | P47989 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17293972 | 0.88 | ALDH1A1 (0.50) | SLC6A9XDHALDH1A1IRAK4HTT | |
| SCHEMBL20944764 | 0.85 | LMNA (0.48) | SLC6A9XDHIRAK4KCNH2 | |
| SCHEMBL4634240 | 0.84 | ALDH1A1 (0.46) | SLC6A9XDHALDH1A1IRAK4 | |
| SCHEMBL14683841 | 0.84 | SLC6A9 (0.52) | SLC6A9KCNH2 | |
| SCHEMBL15144070 | 0.84 | SLC6A9 (0.52) | SLC6A9KCNH2 | |
| SCHEMBL15144069 | 0.84 | SLC6A9 (0.52) | SLC6A9KCNH2 | |
| SCHEMBL16952110 | 0.84 | SLC6A9 (0.44) | SLC6A9XDHIRAK4KCNH2 | |
| SCHEMBL546183 | 0.82 | AR (0.50) | ALDH1A1 | |
| SCHEMBL4037723 | 0.82 | HNF4A (0.56) | SLC6A9ALDH1A1IRAK4 | |
| Hydrochloric Acid SCHEMBL10984138 | 0.81 | AR (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3406142-B1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | CELGENE INT II SARL (CH) | 2020-12-23 | — | — | EP | disclosed |
| US-10239846-B2 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | CELGENE INTERNATIONAL II SÀRL (CH) | 2019-03-26 | — | — | US | disclosed |
| EP-3406142-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | Celgene International II Sàrl (CH) | 2018-11-28 | — | — | EP | disclosed |
| CN-105061350-B | The sphingosine 1-phosphate receptor modulators and Chiral Synthesis of selectivity | 赛尔基因第二国际有限公司 | 2018-05-29 | — | — | CN | disclosed |
| US-20170320839-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2017-11-09 | — | — | US | disclosed |
| US-20170165236-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH | RECEPTOS LLC | 2017-06-15 | — | — | US | disclosed |
| EP-3062792-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH | Celgene International II Sarl (CH) | 2016-09-07 | — | — | EP | disclosed |
| US-9388147-B2 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | Celgene International II Sárl (CH) | 2016-07-12 | — | — | US | disclosed |
| US-20150299149-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2015-10-22 | — | — | US | disclosed |
| WO-2015066515-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH | RECEPTOS, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| US-7220744-B2 | Monocyclic substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | US | disclosed |
| WO-2006072436-A1 | [4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006072436-A1 | [4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006072432-A1 | BENZOYL-TETRAHYDROPYRIDINE AS GLYT-1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
| US-20060148797-A1 | Benzoyl-tetrahydropiperidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | US | disclosed |
| EP-1656361-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005014563-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | SLC6A9 82/4885XDH 1547/4885ALDH1A1 1436/4885 |
| US-20150299149-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | S1PR1, S1PR3, S1PR2 | SLC6A9 2568/4885XDH 4139/4885ALDH1A1 2233/4885 |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | CYP2B6, CYP2D6, CYP1A2 | SLC6A9 1024/4885XDH 338/4885ALDH1A1 52/4885 |
| US-20170165236-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH | S1PR1, S1PR2, S1PR4 | SLC6A9 4123/4885XDH 4341/4885ALDH1A1 3235/4885 |
| US-20060148797-A1 | Benzoyl-tetrahydropiperidine derivatives | GRIN2A, HTR5A, BACE1 | SLC6A9 844/4885XDH 545/4885ALDH1A1 143/4885 |
| US-20170320839-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | S1PR1, S1PR3, S1PR2 | SLC6A9 2568/4885XDH 4139/4885ALDH1A1 2233/4885 |
| US-10239846-B2 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | S1PR1, S1PR3, S1PR2 | SLC6A9 2568/4885XDH 4139/4885ALDH1A1 2233/4885 |
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | SLC1A2, SULT2A1, SLC6A5 | SLC6A9 23/4885XDH 234/4885ALDH1A1 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.